CN101829119A - Cefodizime sodium composition and powder injection - Google Patents
Cefodizime sodium composition and powder injection Download PDFInfo
- Publication number
- CN101829119A CN101829119A CN 201010200559 CN201010200559A CN101829119A CN 101829119 A CN101829119 A CN 101829119A CN 201010200559 CN201010200559 CN 201010200559 CN 201010200559 A CN201010200559 A CN 201010200559A CN 101829119 A CN101829119 A CN 101829119A
- Authority
- CN
- China
- Prior art keywords
- sodium
- cefodizime
- crystal
- composition
- cefodizime sodium
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Images
Landscapes
- Cephalosporin Compounds (AREA)
Abstract
The invention relates to a cefodizime sodium composition, which comprises the following components in percentage by mass: 99.00 to 99.99 percent of cefodizime sodium crystals and 0.01 to 1.00 percent of sodium benzoate. The invention also relates to a preparation containing the cefodizime sodium crystals and the sodium benzoate and a method for preparing the cefodizime sodium crystals. The cefodizime sodium crystals have the advantages of high stability and good liquidity.
Description
Technical field
The invention belongs to medical technical field, relate to a kind of cephalo medicine, is a kind of cefodizime sodium composition powder pin in particular.
Background technology
Cefodizime sodium, its chemical name is: (6R, 7R)-7-[(2-amino-4-thiazolyl)-(methoxyimino) acetamido]-3-[[(5-carboxymethyl-4-methyl-2-thiazolyl) sulfur] methyl]-8-oxo-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-formic acid disodium salt, molecular formula: C
20H
18N
6Na
2O
7S
14Molecular weight: 628.64, structural formula:
Cefodizime sodium is semi-synthetic third generation cephamycin, and gram positive bacteria, negative bacterium are all had antibacterial activity, and is stable to beta lactamase, to cephalosporinase and penicillinase stabilizer pole.Cefodizime sodium is the invention of German Hoechst AG, has antibiotic and immunoregulatory dual nature, is widely used clinically.Clinical pneumonia, bronchitis, pharyngolaryngitis, tonsillitis, pyelonephritis, urinary tract infection, gonococcal urethritis, cholecystitis, cholangitis, gynecological infection, septicemia and the otitis media etc. that are mainly used in due to the sensitive organisms such as Streptococcus, streptococcus pneumoniae.
Crystal is that inside particle molecule, atom or the ion of component is the periodically solid matter of ordered arrangement at three dimensions, has different crystalline state, and its internal structure also has all kinds.The internal structure of crystalline material is called crystal formation, and the different crystal forms of polymorphism is its molecular atoms, the ionic certain rule that is arranged with, and the basis of formation is the interaction between the corpuscle.When satisfying the lattice energy that each configuration molecule is chimeric, accumulation is required, can form different crystal formations.Same crystal has two or more crystal formations to exist, i.e. when unification compound or simple substance crystallization existed the different molecular of two or more crystal structures to arrange simultaneously, this phenomenon was called polymorphic.
Molecule is different in steric configuration, conformation and arrangement in the structure cell of different crystal forms, makes its dissolubility different with dissolution rate, directly influences preparation absorption in vivo, distribution, drainage and metabolism, finally causes the differences of clinical drug effect because of the bioavailability difference.For example in the cimetidine polymorphic, best with A type curative effect, reason is that the dissolving difference of different crystal forms has caused difference for the dissolution and the bioavailability of preparation.There were significant differences for sulfadimidine I type and the crystalline rate of dissolution of II type, makes suspension and give rat oral gavage, and the II type is than I type good absorbing as a result.
Because cefodizime sodium is in the hot conditions instability, the present invention is in order further to improve the stability of cefodizime sodium, crystallization situation to cefodizime sodium has been done further research, has obtained the cefodizime sodium crystal of stable, mobile moderate, the good stability of a kind of specific volume by repetition test.
Summary of the invention
Primary goal of the invention of the present invention is to provide a kind of cefodizime composition of sodium.
Second goal of the invention of the present invention is to provide the powder that contains above-mentioned cefodizime composition of sodium pin.
The 3rd goal of the invention of the present invention is to provide the preparation method of this cefodizime sodium crystal.
According to purpose of the present invention, the technical scheme of employing is:
The present invention relates to a kind of cefodizime composition of sodium, described compositions comprises that mass percent is the sodium benzoate of 99.00%～99.99% cefodizime sodium crystal and 0.01～1.00%, and described crystalline cephem ground Qin sodium uses Cu-K
2 θ of the X-ray powder diffraction that alpha ray measures show characteristic peak at 8.7 °, 10.3 °, 12.4 °, 16.2 °, 16.8 °, 19.2 °, 20.0 °, 20.7 °, 22.0 °, 22.9 ° and 23.7 °.
First preferred version of the present invention is that the mass percent of described sodium benzoate is 0.1～0.5%.
The invention still further relates to the injectable powder that contains described cefodizime sodium crystal and sodium benzoate, this powder pin contains the sodium benzoate that mass percent is 99.00%～99.99% cefodizime sodium crystal and 0.01～1.00%.
The invention still further relates to the preparation method of this cefodizime sodium crystal: cefodizime sodium solid is dissolved in the distilled water, control solution pH value 6.6～7.2, at 12 ℃～20 ℃, add the mixed solvent of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether under preferred 12 ℃～18 ℃ conditions; Be cooled to 4 ℃～10 ℃ after mixed solvent adds, preferred 4 ℃～8 ℃, obtain continuing to stir behind the crystal; Filter, the filter cake washing with alcohol behind the vacuum drying 2～4 hours, obtains the cefodizime sodium crystal.
First preferred version of preparation method of the present invention is: the volume ratio of described anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 1～2: 0.5～1, preferred 1: 1～1.75: 0.5～0.75, more preferably 1: 1.25～1.75: 0.5～0.75.
Second preferred version of preparation method of the present invention is: the mode that described anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether adopt stream to add adds.
The 3rd preferred version of preparation method of the present invention is: the speed that anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether stream mixed solvent stream add is 4～10ml/ minute, preferred 6～8ml/ minute.
The 4th preferred version of preparation method of the present invention is: the mixing speed when dripping dry isobutanol and absolute ether is 80～120 rev/mins, preferred 100～120 rev/mins.
The 5th preferred version of preparation method of the present invention is: obtain continuing to stir 2～4 hours behind the crystal, mixing speed is 60～80 rev/mins, preferred 65～75 rev/mins.
Below technical scheme of the present invention is described in detail:
The present invention relates to a kind of cefodizime composition of sodium, described compositions comprises that mass percent is the sodium benzoate of 99.00%～99.99% cefodizime sodium crystal and 0.01～1.00%, the X-ray powder diffraction figure of described cefodizime sodium crystal as shown in Figure 1, and confirm through overtesting, after cefodizime sodium crystal and sodium benzoate mix, the X-ray powder diffraction figure of cefodizime sodium crystal is consistent, and the crystal structure that does not influence cefodizime sodium with mixing of sodium benzoate is described.
The invention still further relates to the preparation method of this cefodizime sodium crystal: cefodizime sodium solid is dissolved in the distilled water, control solution pH value 6.6～7.2, at 15 ℃～20 ℃ dirty mixed solvents that add anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether of condition, the speed of dropping is 6～8ml/ minute; The volume ratio of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 1.25～1.75: 0.5～0.75, and mixing speed is 100～120 rev/mins; Be cooled to 4 ℃～10 ℃ after mixed solvent adds, preferred 4 ℃～8 ℃, obtain continuing to stir 65～75 rev/mins of mixing speeds 2～4 hours behind the crystal; Filter, the filter cake washing with alcohol behind the vacuum drying 2～4 hours, obtains the cefodizime sodium crystal.
In preparation method of the present invention, the present invention has obtained a kind of new cefodizime sodium crystal by the meticulous control to crystallization condition, has the described X-ray powder diffraction curve of Fig. 1.The present invention is by to the control of temperature, pH value, flow acceleration, mixing speed, thus the crystallization process of strict control solution more.In the crystallization process of cefodizime sodium, three kinds of mixed solvents that solvent forms have been adopted, thereby make solution form the system of cefodizime sodium-isopropyl alcohol-alcohol-ether-water, this system has the long steady district of crystallization Jie, the adding of organic solvent slowly descends the saturation solubility of cefodizime sodium, thereby the system degree of supersaturation of making slowly rises, thereby can be by the control of convective acceleration, the speed of growth and the crystalline speed of growth of control nucleus, thus crystalline granularity controlled.Simultaneously crystalline temperature is controlled, the temperature that stream adopts when adding organic solvent is 15 ℃～20 ℃, is cooled to 5 ℃～10 ℃ after organic solvent adds to until crystal formation, the crystalline speed of growth of cooling may command.By above-mentioned condition to crystalline control, thereby obtain that crystal size is more evenly distributed, granularity is moderate, thereby make the cefodizime sodium of acquisition have good flowability.
Through experiment confirm, being greatly improved of cefodizime sodium crystal stability of the present invention, specific volume is stable simultaneously.
Description of drawings
Fig. 1 is the X-ray powder diffraction figure of embodiment 1 cefodizime sodium crystal.
The specific embodiment
Embodiment 1: the preparation of cefodizime sodium crystal
Cefodizime sodium solid is dissolved in the distilled water, control solution pH value 6.6～7.2, at 15 ℃ of dirty mixed solvents that add anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether of condition, the speed of dropping is 6ml/ minute; The volume ratio of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 1.25: 0.5, and mixing speed is 100 rev/mins; After adding, mixed solvent is cooled to 4 ℃; Obtain continuing to stir 65 rev/mins of mixing speeds 2 hours behind the crystal; Filter, filter cake is with washing with alcohol 2～3 times, behind the vacuum drying 2 hours, obtains the cefodizime sodium crystal.
The X-ray powder diffraction figure that this crystal by adopting Cu-K alpha ray measures as shown in Figure 1.
Embodiment 2: the preparation of cefodizime sodium crystal
Cefodizime sodium solid is dissolved in the distilled water, control solution pH value 6.6～7.2, at 20 ℃ of dirty mixed solvents that add water isopropyl alcohol, dehydrated alcohol and absolute ether of condition, rate of addition is 8ml/ minute; The volume ratio of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 1.75: 0.75, and mixing speed is 120 rev/mins; Be cooled to 10 ℃ after mixed solvent adds, obtain continuing to stir 75 rev/mins of mixing speeds 4 hours behind the crystal; Filter, the filter cake washing with alcohol behind the vacuum drying 4 hours, obtains the cefodizime sodium crystal.The analysis showed that through powder X-ray RD detector, conform to the result shown in the accompanying drawing 1.
Embodiment 3: the preparation of cefodizime sodium crystal
Cefodizime sodium solid is dissolved in the distilled water, the pH value 6.6～7.2 of control solution, drips the mixed solvent of water isopropyl alcohol, dehydrated alcohol and absolute ether under 15 ℃ of conditions, the speed of dropping is 7ml/ minute; The volume ratio of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 1.5: 0.7, and mixing speed is 110 rev/mins; Be cooled to 10 ℃ after mixed solvent adds, obtain continuing to stir 70 rev/mins of mixing speeds 3 hours behind the crystal; Filter, the filter cake washing with alcohol behind the vacuum drying 3 hours, obtains the cefodizime sodium crystal.The analysis showed that through powder X-ray RD detector, conform to the result shown in the accompanying drawing 1.
Embodiment 4: the preparation of cefodizime sodium crystal
Cefodizime sodium solid is dissolved in the distilled water, the pH value 6.6～7.2 of control solution, drips the mixed solvent of water isopropyl alcohol, dehydrated alcohol and absolute ether under 20 ℃ of conditions, the speed of dropping is 4ml/ minute; The volume ratio of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 2: 1, and mixing speed is 120 rev/mins; Be cooled to 4 ℃ after mixed solvent adds, obtain continuing to stir 80 rev/mins of mixing speeds 3 hours behind the crystal; Filter, the filter cake washing with alcohol behind the vacuum drying 3 hours, obtains the cefodizime sodium crystal.The analysis showed that through powder X-ray RD detector, conform to the result shown in the accompanying drawing 1.
Embodiment 5: the preparation of cefodizime sodium crystal
Cefodizime sodium solid is dissolved in the distilled water, the pH value 6.6～7.2 of control solution, drips the mixed solvent of water isopropyl alcohol, dehydrated alcohol and absolute ether under 12 ℃ of conditions, the speed of dropping is 4ml/ minute; The volume ratio of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 1: 0.5, and mixing speed is 80 rev/mins; Be cooled to 4 ℃～10 ℃ ℃ after mixed solvent adds, obtain continuing to stir 60 rev/mins of mixing speeds 3 hours behind the crystal; Filter, the filter cake washing with alcohol behind the vacuum drying 3 hours, obtains the cefodizime sodium crystal.The analysis showed that through powder X-ray RD detector, conform to the result shown in the accompanying drawing 1.
Embodiment 6: the preparation of cefodizime sodium composition powder pin
Cefodizime sodium composition powder pin, the cefodizime sodium crystal of the embodiment of the invention 1 preparation is fully mixed with sodium benzoate, wherein the percentage by weight of sodium benzoate is 0.1%, carry out tamponade after the mixing, roll lid, examine entirely qualified get final product cefodizime sodium composition powder pin.
Embodiment 7: the preparation of cefodizime sodium composition powder pin
Cefodizime sodium composition powder pin, the cefodizime sodium crystal of the embodiment of the invention 2 preparations is fully mixed with sodium benzoate, wherein the percentage by weight of sodium benzoate is 1%, carry out tamponade after the mixing, roll lid, examine entirely qualified get final product cefodizime sodium composition powder pin.
Embodiment 8: the preparation of cefodizime sodium composition powder pin
Cefodizime sodium composition powder pin, the cefodizime sodium crystal of the embodiment of the invention 3 preparations is fully mixed with sodium benzoate, wherein the percentage by weight of sodium benzoate is 0.01%, carry out tamponade after the mixing, roll lid, examine entirely qualified get final product cefodizime sodium composition powder pin.
Embodiment 9: the preparation of cefodizime sodium composition powder pin
Cefodizime sodium composition powder pin, the cefodizime sodium crystal of the embodiment of the invention 4 preparations is fully mixed with sodium benzoate, wherein the percentage by weight of sodium benzoate is 0.5%, carry out tamponade after the mixing, roll lid, examine entirely qualified get final product cefodizime sodium composition powder pin.
Experimental example 1 influence factor test
1. hot test
Get two batches 01,02 of cefodizime sodium crystal of embodiment 6 gained, simulation listing packing is put in the sealing clean container, under 40 ℃ of temperature, placed 10 days, in the 5th day and sampling in the 10th day, detect result of the test and comparison in 0 day by stable high spot reviews project.
2. high humility test
Get the cefodizime sodium crystal of embodiment 6 gained, simulation listing packing is put in the constant humidity hermetic container, under the condition of 25 ℃ of relative humiditys 90% ± 5%, placed 10 days, in the 5th day and sampling in the 10th day, detect result of the test and comparison in 0 day by stable high spot reviews project.
3. strong illumination test
Get the cefodizime sodium crystal of embodiment 6 gained, simulation listing packing is put in the sealing clean container, and placing illumination is to place 10 days under the condition of 4500lx,, detects result and comparison in 0 day in the 5th day and sampling in the 10th day by stable high spot reviews project.
Influence factor's result of the test sees the following form 1 and table 2.
Table 1: injection cefodizime sodium influence factor result of the test (batch: 0601)
Table 2: injection cefodizime sodium influence factor result of the test (batch: 0602)
Table 3: cefodizime sodium influence factor polymer check result
The result shows: this product was placed 10 days down at high temperature (40 ℃) under the condition of simulation listing packing, and removing related substance slightly increases, and outside content slightly reduced, other every indexs did not have significant change.Every index has no significant change under illumination and super-humid conditions.
This has also carried out identical test to the prepared crystalline cephem ground Qin sodium of other embodiment of the present invention with injection cefodizime sodium aseptic powder injection, and the result of its acquisition is similar.
Experimental example 2: accelerated tests
Get six batches of cefodizime sodium crystal of embodiment 9 gained, simulation listing packing is put in the sealing clean container, places 6 months under 40 ℃ of temperature, at duration of test once, each stable high spot reviews project is tested respectively at 1,2,3,6 sampling at the end of month.And check that in quickening June, pyrogen aseptic result of the test sees Table 4～5 to sample.
Table 4 injection cefodizime sodium accelerated test is investigated the result
Table 5 injection cefodizime sodium quickens polymer in June, aseptic, pyrogen test result
By the accelerated test result as can be known, this product was investigated through accelerated test in 6 months, related substance slightly increases, content slightly reduces, character becomes yellow crystalline powder by little yellow crystalline powder, significant change does not take place in all the other every indexs, and all in prescribed limit, accelerated test is aseptic all up to specification with pyrogen test 6 months latter stages.Show this product by above-mentioned packing, basicly stable under the condition of 25 ℃ ± 2 ℃ of temperature, relative humidity 60% ± 10%.
This has also carried out identical test to the prepared crystalline cephem ground Qin sodium of other embodiment of the present invention with injection cefodizime sodium aseptic powder injection, and the result of its acquisition is similar.
Experimental example 3: long term test
Get six batches of cefodizime sodium crystal of embodiment 8 gained, simulation listing packing is put in the sealing clean container, places 36 months under 6 ℃ ± 2 ℃ conditions of temperature, at duration of test once, each inspection item is tested respectively at the 3rd, 6,9,12,18,24,36 sampling at the end of month.Result of the test sees Table 6,7:
Table 6: injection cefodizime sodium long term test is investigated the result
Table 7: the aseptic and pyrogen test result of injection cefodizime sodium long term test
By long-term test results as can be known, this product was investigated through long term test in 24 months, and significant change does not all take place every index, all in prescribed limit.Long term test 24 months is aseptic, pyrogen and bacterial endotoxin inspection are all up to specification.Show this product by above-mentioned packing, basicly stable under the condition of 6 ℃ ± 2 ℃ of temperature.
This has also carried out identical test to the prepared crystalline cephem ground Qin sodium of other embodiment of the present invention with injection cefodizime sodium aseptic powder injection, and the result of its acquisition is similar.
Claims (9)
1. cefodizime composition of sodium, it is characterized in that, described compositions comprises that mass percent is the sodium benzoate of 99.00%～99.99% cefodizime sodium crystal and 0.01～1.00%, and 2 θ of the X-ray powder diffraction that described crystalline cephem ground Qin sodium use Cu-K alpha ray measures show characteristic peak at 8.7 °, 10.3 °, 12.4 °, 16.2 °, 16.8 °, 19.2 °, 20.0 °, 20.7 °, 22.0 °, 22.9 ° and 23.7 °.
2. cefodizime composition of sodium according to claim 1 is characterized in that, the mass percent of described sodium benzoate is 0.1～0.5%.
3. one kind contains each described cefodizime composition of sodium of claim 1～2, it is characterized in that described powder pin contains the sodium benzoate that mass percent is 99.00%～99.99% cefodizime sodium crystal and 0.01～1.00%.
4. cefodizime composition of sodium according to claim 1, it is characterized in that, the preparation method of described cefodizime sodium crystal is, cefodizime sodium solid is dissolved in the distilled water, control solution pH value 6.6～7.2, at 12 ℃～20 ℃, add the mixed solvent of anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether under preferred 12 ℃～18 ℃ conditions, be cooled to 4 ℃～10 ℃ after mixed solvent adds, preferred 4 ℃～8 ℃, obtain continuing to stir behind the crystal; Filter, the filter cake washing with alcohol behind the vacuum drying 2～4 hours, obtains the cefodizime sodium crystal.
5. cefodizime composition of sodium according to claim 4, it is characterized in that, the volume ratio of described anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether is 1: 1～2: 0.5～1, preferred 1: 1～1.75: 0.5～0.75, more preferably 1: 1.25～1.75: 0.5～0.75.
6. cefodizime composition of sodium according to claim 4 is characterized in that, the method that described anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether adopt stream to add adds.
7. cefodizime composition of sodium according to claim 6 is characterized in that, the speed that anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether stream add is 4～10ml/ minute, preferred 6～8ml/ minute.
8. cefodizime composition of sodium according to claim 6 is characterized in that, mixing speed is 80～120 rev/mins when dripping anhydrous isopropyl alcohol, dehydrated alcohol and absolute ether, preferred 100～120 rev/mins.
9. cefodizime composition of sodium according to claim 4 is characterized in that, obtains continuing to stir 2～4 hours behind the white crystal, and mixing speed is 60～80 rev/mins, preferred 65～75 rev/mins.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102005590A CN101829119B (en) | 2010-06-13 | 2010-06-13 | Cefodizime sodium composition and powder injection |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102005590A CN101829119B (en) | 2010-06-13 | 2010-06-13 | Cefodizime sodium composition and powder injection |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101829119A true CN101829119A (en) | 2010-09-15 |
| CN101829119B CN101829119B (en) | 2011-11-30 |
Family
ID=42713441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102005590A Active CN101829119B (en) | 2010-06-13 | 2010-06-13 | Cefodizime sodium composition and powder injection |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101829119B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102796118A (en) * | 2012-05-29 | 2012-11-28 | 浙江亚太药业股份有限公司 | Cefodizime sodium compound solid, method for preparing same and pharmaceutical preparation of cefodizime sodium compound solid |
| CN103191061A (en) * | 2013-03-29 | 2013-07-10 | 山东罗欣药业股份有限公司 | Cefbuperazone sodium composition powder for injection and preparation method thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1442144A (en) * | 2003-03-12 | 2003-09-17 | 广州贝氏药业有限公司 | Antibacterial composite medicine |
| CN101723958A (en) * | 2008-10-22 | 2010-06-09 | 丽珠医药集团股份有限公司 | Cefodizime sodium medicament and preparation method thereof |
-
2010
- 2010-06-13 CN CN2010102005590A patent/CN101829119B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1442144A (en) * | 2003-03-12 | 2003-09-17 | 广州贝氏药业有限公司 | Antibacterial composite medicine |
| CN101723958A (en) * | 2008-10-22 | 2010-06-09 | 丽珠医药集团股份有限公司 | Cefodizime sodium medicament and preparation method thereof |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102796118A (en) * | 2012-05-29 | 2012-11-28 | 浙江亚太药业股份有限公司 | Cefodizime sodium compound solid, method for preparing same and pharmaceutical preparation of cefodizime sodium compound solid |
| CN102796118B (en) * | 2012-05-29 | 2013-12-04 | 浙江亚太药业股份有限公司 | Cefodizime sodium compound solid, method for preparing same and pharmaceutical preparation of cefodizime sodium compound solid |
| CN103191061A (en) * | 2013-03-29 | 2013-07-10 | 山东罗欣药业股份有限公司 | Cefbuperazone sodium composition powder for injection and preparation method thereof |
| CN103191061B (en) * | 2013-03-29 | 2015-04-08 | 山东罗欣药业集团股份有限公司 | Cefbuperazone sodium composition powder for injection and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101829119B (en) | 2011-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102838623B (en) | Cefminox sodium compound crystal, preparation method of cefminox sodium compound crystal and sterile powder injection containing cefminox sodium compound crystal | |
| CN104530086B (en) | The new crystal of Cefamandole nafate compounds and crystallization preparation method thereof | |
| CN103524532B (en) | Ceftizoxime sodium compound crystal form, and preparing method and pharmaceutical preparation thereof | |
| CN103601739A (en) | Cefoxitin sodium compound and preparation method thereof | |
| CN101829119B (en) | Cefodizime sodium composition and powder injection | |
| CN103304582B (en) | Cefoxitin sodium compound, preparation method and pharmaceutical composition thereof | |
| CN103012434A (en) | Cefathiamidine compound crystal and preparation method as well as pharmaceutical composition thereof | |
| CN104644630A (en) | Amoxicillin sodium and sulbactam sodium preparation for injection and preparation method thereof | |
| CN110143957B (en) | Preparation method of cefditoren pivoxil ring-opening product | |
| CN103467494B (en) | Novel crystal form of cefdinir and preparation method thereof | |
| CN102942577B (en) | Cefoxitin sodium compound-containing pharmaceutical composition | |
| CN102973569B (en) | Pharmaceutical composition with cefminox sodium sterile mixed powder form | |
| CN102258521B (en) | Cefodizime Sodium composition and method of making the same | |
| CN104622695A (en) | Cefoxitin sodium powder preparation for injection | |
| CN102936254B (en) | Drug composition containing ceftizoxime sodium compound | |
| CN105622635B (en) | One kind reduces anaphylactoid ceftizoxime sodium novel crystal form and its preparation | |
| CN103304604B (en) | Clindamycin phosphate compound and preparation method and pharmaceutical composition thereof | |
| CN102363621B (en) | Cefminox sodium hexahydrate, preparation method thereof and pharmaceutical composition containing hexahydrate | |
| CN105037391A (en) | Cefamandole nafate compound and preparation thereof | |
| CN103159785B (en) | A kind of cefuroxime lysine and preparation thereof | |
| CN103159784A (en) | Cefuroxime lysine and preparation thereof | |
| CN103497205B (en) | New crystal of a kind of Glaxo) and preparation method thereof | |
| CN103130821B (en) | A kind of cefuroxime lysine and preparation thereof | |
| CN103145734B (en) | A kind of cefuroxime lysine and preparation thereof | |
| CN102875575B (en) | Cefodizime sodium compound and preparation thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C56 | Change in the name or address of the patentee |
Owner name: SHANDONG LUOXIN PHARMACY GROUP CO., LTD. Free format text: FORMER NAME: SHANDONG LUOXIN PHARMACY STOCK CO., LTD. |
|
| CP01 | Change in the name or title of a patent holder |
Address after: Seven of 276000 Shandong province Linyi city Luozhuang District Patentee after: Shandong Luo Xin Pharmaceutical Group Plc Address before: Seven of 276000 Shandong province Linyi city Luozhuang District Patentee before: SHANDONG LUOXIN PHARMACY STOCK Co., LTD. |